Loading stock data…
$7.40-0.20 (-2.63%)
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
NeurAxis, Inc. in the Healthcare sector is trading at $7.40 with a market capitalization of $99M. Wall Street consensus targets $11.00 (2 analysts), implying a +48.6% move over the next 12 months. The stock is currently 21% below its 52-week high of $9.33, remaining 12.1% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.93M↑ | $1.61M↑ | $968,127↑ | $811,414↓ | $894,086 |
| Gross Profit | $1.66M↑ | $1.39M↑ | $826,476↑ | $675,927↓ | $747,443 |
| Operating Income | -$2.12M↓ | -$1.74M↓ | -$1.72M↑ | -$2.10M↓ | -$1.72M |
| Net Income | -$2.09M↓ | -$1.76M↓ | -$1.71M↑ | -$2.12M↓ | -$1.69M |
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimula...